Michael Jay Fisher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Jay Fisher has a total of 606 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Hutter
St Anna Kinderspital, Department of Pediatrics, Medical University of Vienna, Vienna, Austria
10 shared publications - Jordan R. Hansford
Michael Rice Centre for Hematology and Oncology, Women’s and Children’s Hospital, South Australia Health and Medical Research Institute, South Australia Immunogenomics Cancer Institute, Adelaide University, Ade-laide, SA 5000, Australia
10 shared publications - Nathan J. Robison
Children's Hospital of Los Angeles 14 Los Angeles, CA
10 shared publications - Stefan M. Pfister
Hopp Children's Cancer Center Heidelberg (KiTZ)
10 shared publications - Uri Tabori
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada
10 shared publications - Adam Resnick
Center for Data-Driven Discovery in Biomedicine, Children’s Hospital of Philadelphia
9 shared publications
Latest Publications
- 18 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
A framework for prioritizing novel agents in malignant peripheral nerve sheath tumor trials: A report from the neurofibromatosis clinical trials consortium
Malignant peripheral nerve sheath tumors (MPNST) are soft tissue sarcomas, occurring either in people with neurofibromatosis type 1 (NF1) or sporadically, with a tendency for recurrence and distant metastases and poor survival rates. The only proven curative treatment is complete oncologic resection, and there is currently no FDA-approved drug for the treatment of MPNST. Multiple clinical trials have failed to achieve improvement in survival, and novel therapeutic approaches are urgently needed. To address this need, members of the MPNST Committee of the Congressionally Directed Medical Research Programs-supported Neurofibromatosis Clinical Trials Consortium convened to develop a framework to prioritize therapeutic agents with the highest potential for successful clinical development. We review the potential agents that may be prioritized and propose a methodology to evaluate available preclinical and clinical data. Increasing the availability and use of diverse preclinical models and defining the best preclinical endpoints prior to clinical translation can increase the success of clinical trials. Subsequently, utilizing a platform trial design can accelerate the clinical development process and facilitate patient accrual. It is imperative to foster collaborations with pharmaceutical companies and community partners. The integration of preclinical and clinical evaluation in an iterative and informative process can accelerate effective clinical development.
- 18 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
A framework for prioritizing novel agents in malignant peripheral nerve sheath tumor trials: A report from the neurofibromatosis clinical trials consortium
Malignant peripheral nerve sheath tumors (MPNST) are soft tissue sarcomas, occurring either in people with neurofibromatosis type 1 (NF1) or sporadically, with a tendency for recurrence and distant metastases and poor survival rates. The only proven curative treatment is complete oncologic resection, and there is currently no FDA-approved drug for the treatment of MPNST. Multiple clinical trials have failed to achieve improvement in survival, and novel therapeutic approaches are urgently needed. To address this need, members of the MPNST Committee of the Congressionally Directed Medical Research Programs-supported Neurofibromatosis Clinical Trials Consortium convened to develop a framework to prioritize therapeutic agents with the highest potential for successful clinical development. We review the potential agents that may be prioritized and propose a methodology to evaluate available preclinical and clinical data. Increasing the availability and use of diverse preclinical models and defining the best preclinical endpoints prior to clinical translation can increase the success of clinical trials. Subsequently, utilizing a platform trial design can accelerate the clinical development process and facilitate patient accrual. It is imperative to foster collaborations with pharmaceutical companies and community partners. The integration of preclinical and clinical evaluation in an iterative and informative process can accelerate effective clinical development.
- Top Cited PapersOpen Access
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (10) , 849-860
Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II)
PURPOSE: Neurofibromatosis type 1 (NF1)–associated plexiform neurofibroma (PN) can substantially affect quality of life. The capsule and granule formulations of selumetinib (ARRY-142886, AZD6244) are approved for pediatric patients with symptomatic, inoperable NF1-PN (age ≥1 to 3 years, region dependent). SPRINKLE (ClinicalTrials.gov identifier: NCT05309668 ) assessed pharmacokinetics (PK), safety, and palatability of the selumetinib granule formulation in children (age ≥1 to 2 (dose equivalent) twice a day in 28-day cycles. Primary objectives assessed single-dose selumetinib PK exposure (area under concentration-time curve from time 0-12 hours [AUC 0-12 ]) in GCs and selumetinib safety. Secondary objectives assessed selumetinib and N-desmethyl selumetinib metabolite PK (single/multiple dose), and palatability. At first data cutoff (April 8, 2024), all participants had completed ≥3 cycles. RESULTS: There were 36 participants (GC1: n = 15, GC2: n = 17, JC: n = 4). Geometric mean (95% CI) selumetinib AUC 0-12 (single dose) in GC1 (n = 13) and GC2 (n = 15) was 1,902 (1,647 to 2,197) and 1,699 (1,436 to 2,009) h × ng/mL, respectively. Primary PK end point was met: 95% CIs of AUC 0-12 (single dose) were within the acceptance range on the basis of the capsule formulation exposure. Median duration of exposure was approximately 11 months (range, 2.7-25.3). 97.2% of participants had ≥1 treatment-related adverse event; most were grade 1 or 2 and none led to discontinuation or dose reduction. Most participants reported swallowing the medication without problems. CONCLUSION: Selumetinib granule formulation (25 mg/m 2 dose equivalent, twice a day) had comparable exposure to selumetinib capsule formulation, and was palatable with a manageable safety profile. Selumetinib granule formulation is potentially suitable for young children with NF1-PN who cannot swallow capsules.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (10) , 849-860
Top Cited PapersOpen AccessPharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II)
PURPOSE: Neurofibromatosis type 1 (NF1)–associated plexiform neurofibroma (PN) can substantially affect quality of life. The capsule and granule formulations of selumetinib (ARRY-142886, AZD6244) are approved for pediatric patients with symptomatic, inoperable NF1-PN (age ≥1 to 3 years, region dependent). SPRINKLE (ClinicalTrials.gov identifier: NCT05309668 ) assessed pharmacokinetics (PK), safety, and palatability of the selumetinib granule formulation in children (age ≥1 to 2 (dose equivalent) twice a day in 28-day cycles. Primary objectives assessed single-dose selumetinib PK exposure (area under concentration-time curve from time 0-12 hours [AUC 0-12 ]) in GCs and selumetinib safety. Secondary objectives assessed selumetinib and N-desmethyl selumetinib metabolite PK (single/multiple dose), and palatability. At first data cutoff (April 8, 2024), all participants had completed ≥3 cycles. RESULTS: There were 36 participants (GC1: n = 15, GC2: n = 17, JC: n = 4). Geometric mean (95% CI) selumetinib AUC 0-12 (single dose) in GC1 (n = 13) and GC2 (n = 15) was 1,902 (1,647 to 2,197) and 1,699 (1,436 to 2,009) h × ng/mL, respectively. Primary PK end point was met: 95% CIs of AUC 0-12 (single dose) were within the acceptance range on the basis of the capsule formulation exposure. Median duration of exposure was approximately 11 months (range, 2.7-25.3). 97.2% of participants had ≥1 treatment-related adverse event; most were grade 1 or 2 and none led to discontinuation or dose reduction. Most participants reported swallowing the medication without problems. CONCLUSION: Selumetinib granule formulation (25 mg/m 2 dose equivalent, twice a day) had comparable exposure to selumetinib capsule formulation, and was palatable with a manageable safety profile. Selumetinib granule formulation is potentially suitable for young children with NF1-PN who cannot swallow capsules.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S4. Other molecular alterations reported.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S4. Other molecular alterations reported.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S1. NTRK fusion type and histology.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S1. NTRK fusion type and histology.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S1. Diagram of population patients.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S1. Diagram of population patients.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S5. Method of NTRK fusion detection as reported by participating centers.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S5. Method of NTRK fusion detection as reported by participating centers.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S3. Survival outcome.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S3. Survival outcome.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S2. Responses based on clinical assessment for each line of therapy. Non-targeted therapy and TRKi given concurrently in a specific line were excluded.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S2. Responses based on clinical assessment for each line of therapy. Non-targeted therapy and TRKi given concurrently in a specific line were excluded.